v3.26.1
Segment Reporting - Schedule of Research and Development Expenses (Details) - Research and Development Activities Segment - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]    
External clinical development expenses $ 5,329,238 $ 4,917,271
Personnel related and stock-based compensation 1,712,798 1,337,750
Other research and development expenses 893,644 942,236
Total research and development expenses 7,935,680 7,197,257
SBI-100    
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]    
External clinical development expenses 0 2,241
nimacimab    
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]    
External clinical development expenses $ 5,329,238 $ 4,915,030